title: Comment: Reasons for early abacavir discontinuation in HIV-infected patients.
authors.forename: Jorge
authors.initials: J
authors.lastname: Parra-Ruiz
authors.forename: Mariela
authors.initials: M
authors.lastname: Martínez-Ramírez
authors.forename: Leopoldo
authors.initials: L
authors.lastname: Muñoz-Medina
authors.forename: Cristina
authors.initials: C
authors.lastname: Serrano-Falcón
authors.forename: José
authors.initials: J
authors.lastname: Hernández-Quero
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects; D016312:Treatment Refusal; D015215:Zidovudine / Q000009:adverse effects; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D015215:Zidovudine; D000099227:Abacavir; C418262:abacavir, lamivudine, and zidovudine drug combination